Third Harmonic Bio Investor Relations Material
Latest events
Study Update
Third Harmonic Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Third Harmonic Bio Inc
Access all reports
Third Harmonic Bio Inc., operating under the ticker THRD, is a clinical-stage biopharmaceutical company dedicated to developing therapies for inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. The company is actively working on novel treatments and focuses on KIT inhibition, a key regulatory mechanism in mast cell function, which plays a substantial role in inflammatory responses across these conditions. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
THRD
Country
🇺🇸 United States